Filing Details

Accession Number:
0001209191-20-059410
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-19 16:39:39
Reporting Period:
2020-11-17
Accepted Time:
2020-11-19 16:39:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1664710 Keros Therapeutics Inc. KROS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1568077 Tomer Kariv C/O Keros Therapeutics, Inc.
99 Hayden Avenue, Suite 120, Building E
Lexington MA 02421
Yes No Yes No
1726029 L.p. Iv (Cayman) Pontifax 14 Shenkar Street, Beit Ofek
Herzliya Pituach L3 46140
No No Yes No
1726030 L.p. Iv (China) Pontifax 14 Shenkar Street, Beit Ofek
Herzliya Pituach L3 46140
No No Yes No
1726039 Pontifax (Israel) Iv, L.p. 14 Shenkar Street, Beit Ofek
Herzliya Pituach L3 46140
No No Yes No
1793769 L.p. Fund Stage Late Pontifax 14 Shenkar Street, Beit Ofek
Herzliya Pituach L3 46140
No No Yes No
1793770 Ltd. Gp Stage Late Pontifax 14 Shenkar Street, Beit Ofek
Herzliya Pituach L3 46140
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-17 26,634 $50.00 2,288,151 No 4 P Indirect See footnote
Common Stock Acquisiton 2020-11-17 12,966 $50.00 1,122,768 No 4 P Indirect See footnote
Common Stock Acquisiton 2020-11-17 14,400 $50.00 1,228,326 No 4 P Indirect See footnote
Common Stock Acquisiton 2020-11-17 6,000 $50.00 155,262 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
  2. The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
  3. The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
  4. The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds.
  5. Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.